BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
The deal could bring BoomRay up to $900 million in milestone payments and royalties as the companies advance a preclinical radioligand therapy asset.
- On Sept 22, 2026, Boomray Pharmaceuticals Ltd. announced an exclusive global license agreement with Novartis Pharma for an undisclosed preclinical RLT asset.
- Under the agreement, BoomRay is eligible to receive up to USD 900 million in upfront, development, regulatory, and sales milestone payments, plus royalties on future global net sales.
- "We are honored and excited to enter into this agreement," said Bo Shan, Chief Executive Officer of BoomRay. "Radioligand therapies represent an important frontier in oncology," added Shiva Malek, Global Head of Oncology, Biomedical Research at Novartis.
- BFC Group acted as the financial advisor for the transaction, which pairs BoomRay's discovery and development capabilities with Novartis's global expertise in RLTs.
- Based in SUZHOU, China, BoomRay continues to advance its proprietary pipeline of First-in-Class and Best-in-Class RLTs, aiming to address critical unmet medical needs in Oncology.
43 Articles
43 Articles
The Berkshire Eagle
BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today announced that it has entered into an exclusive global license agreement with…
BoomRay, Novartis Pharma sign $900m deal for radioligand therapy
The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net sales. The The post BoomRay and Novartis Pharma sign $900m deal for radioligand therapy appeared first on Pharmaceutical Business review.
Novartis licenses BoomRay radioligand asset for $900M - European Biotechnology Magazine
Novartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma group’s core oncology platforms.
Coverage Details
Bias Distribution
- 76% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
